Loading...
Loading...
Duality Biotherapeutics Inc/ADR
Duality Biotherapeutics Inc/ADR. Spoken Alpha tracks DYBTY's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks DYBTY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for DYBTY.
curl https://api.spokenalpha.com/v1/companies/DYBTY| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.70 | $2.46 | +9.7% | -8.5% | -8.4% |
| Q4 FY2026 | $3.13 | $2.63 | +18.9% | 0.0% | -1.2% |
| Q3 FY2026 | $2.59 | $2.46 | +5.4% | -10.0% | -11.0% |
| Q2 FY2026 | $2.73 | $2.47 | +10.4% | -0.9% | -2.6% |
| Q1 FY2025 | $2.87 | $2.55 | +12.7% | +0.3% | +1.1% |
| Q4 FY2025 | $2.85 | $2.51 | +13.5% | +1.9% | -1.1% |
| Q3 FY2025 | $3.14 | $2.72 | +15.6% | -8.5% | -6.9% |
| Q2 FY2025 | $3.14 | $2.75 | +14.1% | +0.2% | -1.4% |
| Q1 FY2024 | $2.97 | $2.63 | +12.9% | -8.0% | -6.5% |
| Q4 FY2024 | $3.15 | $2.72 | +15.8% | -1.9% | -2.8% |